Immunotherapy provides the best approach
to reduce the high mortality
of metastatic breast cancer (BC). We demonstrate a chemo-immunotherapy
approach, which utilizes a liposomal carrier to simultaneously trigger
immunogenic cell death (ICD) as well as interfere in the regionally
overexpressed immunosuppressive effect of indoleamine 2,3-dioxygenase
(IDO-1) at the BC tumor site. The liposome was constructed by self-assembly
of a phospholipid-conjugated prodrug, indoximod (IND), which inhibits
the IDO-1 pathway, followed by the remote loading of the ICD-inducing
chemo drug, doxorubicin (DOX). Intravenous injection of the encapsulated
two-drug combination dramatically improved the pharmacokinetics and
tumor drug concentrations of DOX and IND in an orthotopic 4T1 tumor
model in syngeneic mice. Delivery of a threshold ICD stimulus resulted
in the uptake of dying BC cells by dendritic cells, tumor antigen
presentation and the activation/recruitment of naïve T-cells. The subsequent activation
of perforin- and IFN-γ releasing cytotoxic T-cells induced robust
tumor cell killing at the primary as well as metastatic tumor sites.
Immune phenotyping of the tumor tissues confirmed the recruitment
of CD8+ cytotoxic T lymphocytes (CTLs), disappearance of
Tregs, and an increase in CD8+/FOXP3+ T-cell
ratios. Not only does the DOX/IND-Liposome provide a synergistic antitumor
response that is superior to a DOX-only liposome, but it also demonstrated
that the carrier could be effectively combined with PD-1 blocking
antibodies to eradicate lung metastases. All considered, an innovative
nano-enabled approach has been established to allow deliberate use
of ICD to switch an immune deplete to an immune replete BC microenvironment,
allowing further boosting of the response by coadministered IDO inhibitors
or immune checkpoint blocking antibodies.
Background: Increased numbers of myeloid-derived suppressor cells (MDSCs) are positively correlated with poor prognosis and reduced survivals of cancer patients. They play central roles in tumor immune evasion and tumor metastasis. However, limited data are available on phenotypic/transcriptomic characteristics of the different MDSCs subsets in cancer. These cells include immature (I-MDSCs), monocytic (M-MDSCs), and polymorphonuclear/ granulocytic (PMN-MDSCs). Methods: Phenotypic characterization of myeloid subsets from 27 colorectal cancer (CRC) patients was assessed by flow cytometric analyses. RNA-sequencing of sorted I-MDSCs, PMN-MDSCs, and antigen-presenting cells (APCs) was also performed. Results: We found that the levels of I-MDSCs and PMN-MDSCs were increased in tumor tissues (TT), compared with normal tissues (NT) in colorectal cancer. Our functional annotation analyses showed that genes associated with histone deacetylase (HDAC) activation-and DNA methylation-mediated transcriptional silencing were upregulated, and histone acetyl transferase (HAT)-related genes were downregulated in tumorinfiltrating I-MDSCs. Moreover, pathways implicated in cell trafficking and immune suppression, including Wnt, interleukin-6 (IL-6), and mitogen-activated protein kinase (MAPK) signaling, were upregulated in I-MDSCs. Notably, PMN-MDSCs showed downregulation in genes related to DNA methylation and HDAC binding. Using an ex vivo model, we found that inhibition of HDAC activation or neutralization of IL-6 in CRC tumor tissues downregulates the expression of genes associated with immunosuppression and myeloid cell chemotaxis, confirming the importance of HDAC activation and IL-6 signaling pathway in MDSC function and chemotaxis. Conclusions: This study provides novel insights into the epigenetic regulations and other molecular pathways in different myeloid cell subsets within the CRC tumor microenvironment (TME), giving opportunities to potential targets for therapeutic benefits.
Heterotopic gastric mucosa (HGM) is gastric mucosal tissue outside the stomach. It can be discovered anywhere throughout the gastrointestinal tract and is mostly asymptomatic. HGM, although rare beyond the ligament of Treitz, should be included in the differential diagnosis in a young patient with a polyp causing obstructive symptoms or bleeding. Very few cases are published in literature. We describe a case of young male who presented with an episode of large amount of melena, from a bleeding jejunal lesion, diagnosed by endoscopy. Laparotomy and wedge resection of the jejunal lesion was done, and histopathology showed gastric heterotopia in a small jejunal diverticulum.
T cell immunoglobulin mucin-3 (TIM-3) is an immune checkpoint identified as one of the key players in regulating T-cell responses. Studies have shown that TIM-3 is upregulated in the tumor microenvironment (TME). However, the precise role of TIM-3 in colorectal cancer (CRC) TME is yet to be elucidated. We performed phenotypic and molecular characterization of TIM-3+ T cells in the TME and circulation of CRC patients by analyzing tumor tissues (TT, TILs), normal tissues (NT, NILs), and peripheral blood mononuclear cells (PBMC). TIM-3 was upregulated on both CD4+ and CD3+CD4− (CD8+) TILs. CD4+TIM-3+ TILs expressed higher levels of T regulatory cell (Tregs)-signature genes, including FoxP3 and Helios, compared with their TIM-3− counterparts. Transcriptomic and ingenuity pathway analyses showed that TIM-3 potentially activates inflammatory and tumor metastatic pathways. Moreover, NF-κB-mediated transcription factors were upregulated in CD4+TIM-3+ TILs, which could favor proliferation/invasion and induce inflammatory and T-cell exhaustion pathways. In addition, we found that CD4+TIM-3+ TILs potentially support tumor invasion and metastasis, compared with conventional CD4+CD25+ Tregs in the CRC TME. However, functional studies are warranted to support these findings. In conclusion, this study discloses some of the functional pathways of TIM-3+ TILs, which could improve their targeting in more specific therapeutic approaches in CRC patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.